Psychedelic Research

DMT, or dimethyltryptamine, has intrigued researchers and psychedelic enthusiasts for its profound effects on consciousness. Known for inducing otherworldly visions, from “machine elves” to mystical figures, some scientists now propose that DMT may play a key role in extraordinary...

A new study published in Scientific Reports revealed that while U.S. healthcare professionals are largely open to the therapeutic potential of psychedelics like psilocybin and MDMA, their understanding of their clinical uses and risks is limited. The research, led by Erin Wang and colleagues from...

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

Missouri is dedicating $5 million from its opioid settlement fund to research the potential of psilocybin in treating opioid use disorder. As Marijuana Moment reported, this funding initiative follows the passage of HB 2010, a state spending bill, and aims to curb overdose deaths by exploring...

A new study published in JAMA Network Open provides a comprehensive look into the effects of year-long medical cannabis use on brain function, with surprising results. Despite the growing popularity of cannabis as a treatment for symptoms like depression, anxiety, pain and insomnia, the study found...

A recent pilot study from the University of Washington School of Medicine shows a low dosage of ketamine can reduce or help eliminate withdrawal symptoms from fentanyl addiction. Medical journal Addiction Science & Clinical Practice published the results Tuesday. A 16-milligram dose of...

A growing body of research suggests that psychedelic mushrooms, specifically those containing psilocybin, may have played a crucial role in the evolution of human consciousness. This conclusion aligns with the “Stoned Ape Hypothesis,” originally proposed by ethnobotanist Terence McKenna...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

A new study is shedding light on the complex brain connectivity changes induced by three psychoactive substances: lysergic acid diethylamide (LSD), 3,4-methylenedioxyamphetamine (MDMA) and d-amphetamine. These compounds, while distinct in their classification—psychedelic, entactogen and stimulant,...

PharmAla Biotech Holdings Inc. (OTC:MDXXF), a Toronto-based biotechnology company, has secured a contract to supply MDMA for a clinical trial conducted by Johns Hopkins Medicine. This marks a significant milestone for the company as it expands its role in providing MDMA and its novel derivatives...

Moxy, known formally as 5-MeO-MIPT, is a powerful synthetic psychedelic that has gained momentum in recent years. Initially synthesized in the 1980s, the compound remained relatively obscure until the early 2000s, when interest in psychedelics grew, particularly among those exploring their...

Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin-based drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical version of psilocybin is designed to avoid inducing the hallucinogenic effects commonly associated...

A recent study published in Translational Psychiatry sheds new light on the diverse factors that influence how individuals experience the effects of LSD (lysergic acid diethylamide). The research pooled data from nine double-blind, placebo-controlled studies, and examined the responses of 213...

Psychedelics, such as psilocybin, DMT, mescaline and LSD have attracted increasing attention for their potential mental health benefits. These substances elicit profound acute subjective effects, ranging from altered cognition and perception to intense emotional experiences. While mystical...

A recent open-label study conducted by the University of Copenhagen and the National Institute on Alcohol Abuse and Alcoholism has revealed that a single dose of psilocybin, a psychedelic compound found in magic mushrooms, could offer a novel and effective treatment for alcohol use disorder (AUD)....